Virginia Kaklamani Selected Research

Therapeutics

1/2022	The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
1/2022	Targeting aberrant replication and DNA repair events for treating breast cancers.
12/2021	Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
1/2021	Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
1/2020	Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression.
1/2020	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
1/2019	Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
3/2013	Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant.
1/2013	A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
7/2010	Can novel genetic polymorphisms predict response to therapy in acute myeloid leukemia?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Virginia Kaklamani Research Topics

Disease

24	Breast Neoplasms (Breast Cancer) 01/2022 - 04/2004
19	Neoplasms (Cancer) 01/2022 - 01/2003
5	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2005
3	Disease Progression 01/2019 - 05/2007
3	Carcinogenesis 06/2016 - 12/2007
3	Colorectal Neoplasms (Colorectal Cancer) 05/2010 - 05/2005
2	Triple Negative Breast Neoplasms 01/2021 - 01/2020
2	Insulin Resistance 01/2013 - 09/2011
2	Prostatic Neoplasms (Prostate Cancer) 09/2011 - 09/2004
1	Nausea 01/2021
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020
1	Pathologic Complete Response 01/2020
1	Ductal Carcinoma 01/2020
1	Weight Loss (Weight Reduction) 08/2017
1	Fatigue 05/2013
1	Stomatitis 05/2013
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2013
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2013
1	Malaria 01/2013
1	Liver Diseases (Liver Disease) 01/2013
1	Neutropenia 01/2013
1	Obesity 09/2011
1	Cardiovascular Diseases (Cardiovascular Disease) 08/2010
1	Exanthema (Rash) 08/2010
1	Cardiotoxicity 08/2010
1	Diarrhea 08/2010
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/2010
1	Adenocarcinoma 05/2010
1	Colonic Neoplasms (Colon Cancer) 12/2007

Drug/Important Bio-Agent (IBA)

7	Transforming Growth Factor-beta Type I ReceptorIBA 05/2010 - 02/2004
5	Estrogen ReceptorsIBA 01/2022 - 11/2006
5	Transforming Growth Factor beta (TGF-beta)IBA 05/2009 - 01/2003
4	Trastuzumab (Herceptin)FDA Link 12/2021 - 04/2004
3	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2011
3	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2010
3	ErbB Receptors (EGF Receptor)IBA 12/2021 - 01/2020
2	Estrogens (Estrogen)FDA Link 01/2022 - 06/2016
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 05/2010
2	Everolimus FDA Link 01/2020 - 01/2019
2	AnthracyclinesIBA 05/2019 - 08/2010
2	taxaneIBA 05/2019 - 08/2010
2	Hormones (Hormone)IBA 01/2019 - 08/2010
2	human ERBB2 proteinIBA 05/2013 - 01/2013
2	Sorafenib (BAY 43-9006)FDA Link 05/2013 - 01/2013
2	Capecitabine (Xeloda)FDA Link 05/2013 - 08/2010
2	Bevacizumab (Avastin)FDA Link 05/2013 - 04/2004
2	AdiponectinIBA 01/2013 - 09/2011
1	olaparibIBA 01/2022
1	carbazoleIBA 01/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022
1	Antidepressive Agents (Antidepressants)IBA 01/2022
1	Imipramine (Janimine)FDA LinkGeneric 01/2022
1	Carboplatin (JM8)FDA LinkGeneric 12/2021
1	Ado-Trastuzumab EmtansineIBA 12/2021
1	B7-H1 AntigenIBA 12/2021
1	pertuzumabIBA 12/2021
1	atezolizumabIBA 12/2021
1	Docetaxel (Taxotere)FDA Link 12/2021
1	Triglycerides (Triacylglycerol)IBA 01/2021
1	RAD1901IBA 01/2021
1	elacestrantIBA 01/2021
1	2019-nCoV Vaccine mRNA-1273IBA 01/2021
1	BNT162 VaccineIBA 01/2021
1	mRNA VaccinesIBA 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Phosphorus (Red Phosphorus)IBA 01/2021
1	TabletsIBA 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2020
1	Sirolimus (Rapamycin)FDA Link 01/2020
1	PlatinumIBA 01/2020
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2020
1	eribulin FDA Link 05/2019
1	Cytotoxins (Cytolysins)IBA 05/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	Protein Isoforms (Isoforms)IBA 01/2019
1	Growth Factor ReceptorsIBA 01/2019
1	Estrogen Receptor alphaIBA 06/2016
1	Antipsychotic Agents (Antipsychotics)IBA 06/2014
1	Prolactin Receptors (Prolactin Receptor)IBA 06/2014
1	Gemcitabine FDA Link 05/2013
1	Pemetrexed (MTA)FDA Link 04/2013
1	Folic Acid (Vitamin M)FDA LinkGeneric 04/2013
1	Fulvestrant (Faslodex)FDA Link 03/2013
1	C-PeptideIBA 01/2013
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2013
1	Angiogenesis InhibitorsIBA 01/2012
1	Adiponectin ReceptorsIBA 09/2011
1	Letrozole (Femara)FDA LinkGeneric 08/2010
1	Lapatinib (GW572016)FDA Link 08/2010
1	RNA (Ribonucleic Acid)IBA 05/2010
1	Cathepsin DIBA 01/2010
1	EnzymesIBA 01/2010
1	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2009
1	Aligeron (AS 2)IBA 12/2007

Therapy/Procedure

12	Therapeutics 01/2022 - 04/2004
4	Drug Therapy (Chemotherapy) 01/2022 - 01/2012
2	Immunotherapy 12/2021 - 05/2019
1	Precision Medicine 01/2021
1	Neoadjuvant Therapy 01/2020
1	Drug Tapering 05/2013